Holen Sie sich die Stockscreener-App
12.22
2.09%
0.25
Handel nachbörslich:
12.22
Schlusskurs vom Vortag:
$11.97
Offen:
$11.84
24-Stunden-Volumen:
1.54M
Relative Volume:
0.54
Marktkapitalisierung:
$1.74B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-412.89M
KGV:
-3.1658
EPS:
-3.86
Netto-Cashflow:
$-361.93M
1W Leistung:
-2.24%
1M Leistung:
+33.26%
6M Leistung:
-12.78%
1J Leistung:
-74.02%
1-Tages-Spanne:
$11.64
$12.31
1-Wochen-Bereich:
$11.64
$12.68
52-Wochen-Spanne:
$6.36
$47.06
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Vergleichen Sie DYN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
12.22 | 1.75B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics Inc. Recovery Likely Here’s What Data ShowsTrade Risk Assessment & Safe Entry Momentum Stock Tips - beatles.ru
Dyne Therapeutics Inc. Approaches Support With Recovery in SightJuly 2025 Trends & Verified Momentum Stock Watchlist - thegnnews.com
Dyne Therapeutics (DYN) Maintains Hold Rating, $12 Price Target - AInvest
What Technical Tools Say About Dyne Therapeutics Inc. RecoveryJuly 2025 Analyst Calls & Risk Managed Trade Strategies - beatles.ru
Myotonic Dystrophy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin - Barchart.com
Dyne Therapeutics Shares Rise 3.6% After FDA Grants Breakthrough Therapy Status - MSN
Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN - GlobeNewswire Inc.
Should value investors consider Dyne Therapeutics Inc.July 2025 PostEarnings & Safe Capital Growth Stock Tips - thegnnews.com
Pomerantz LLP investigates Dyne Therapeutics for potential securities fraud. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - PR Newswire
Why is Dyne Therapeutics Inc. stock going up2025 EndofYear Setup & Consistent Profit Alerts - thegnnews.com
Can Dyne Therapeutics Inc. expand its profit margins2025 Volatility Report & Comprehensive Market Scan Reports - 선데이타임즈
Dyne Therapeutics Advances DMD Treatment with DYNE-251 Study - MSN
Short Interest Drops in Dyne Therapeutics Inc. After RallyJuly 2025 Setups & High Return Stock Watch Alerts - sundaytimes.kr
Dyne Therapeutics Inc. Shows Risk Reward Favoring UpsideLow Capital High Return Stock Plans Reviewed - 선데이타임즈
Dyne Therapeutics Trading Resumes - AInvest
Is Dyne Therapeutics Reaching New Heights? - StocksToTrade
Dyne Therapeutics price target lowered to $13 from $34 at Oppenheimer - TipRanks
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.00 | DYN Stock News - GuruFocus
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.0 - GuruFocus
Dyne Therapeutics (DYN) Earns Breakthrough Therapy Status for DY - GuruFocus
Dyne Reports Wider Loss in Fiscal Q2 - AOL.com
Dyne Therapeutics stock gains as DYNE-251 receives FDA breakthrough designation - Investing.com Canada
Dyne Therapeutics (DYN) Gains FDA Breakthrough Status for DYNE-2 - GuruFocus
Dyne Therapeutics stock rises after FDA grants breakthrough therapy status By Investing.com - Investing.com Australia
Dyne Therapeutics stock rises after FDA grants breakthrough therapy status - Investing.com
Dyne gets FDA breakthrough therapy status for DMD therapy - Seeking Alpha
Dyne Therapeutics (DYN) Earns Breakthrough Therapy Status for DYNE-251 - GuruFocus
Dyne Therapeutics Gains FDA Breakthrough Designation for DYNE-251 - TipRanks
Dyne Therapeutics Announces Breakthrough Therapy Designation For DYNE-251 - Nasdaq
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation - GuruFocus
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation For Dyne-251 In Duchenne Muscular Dystrophy - TradingView
Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy - Quiver Quantitative
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) - The Manila Times
Dyne Therapeutics Announces FDA Breakthrough Therapy - GlobeNewswire
Dyne Therapeutics: Promising Advancements and FDA Support Drive Buy Rating - TipRanks
What makes Dyne Therapeutics Inc. stock price move sharplyAchieve breakthrough profits with expert advice - Jammu Links News
What is Dyne Therapeutics Inc. company’s growth strategyTremendous growth opportunities - Jammu Links News
Is it the right time to buy Dyne Therapeutics Inc. stockMarket-beating returns - Jammu Links News
Why is Dyne Therapeutics Inc. stock attracting strong analyst attentionAchieve breakthrough gains with expert advice - Jammu Links News
Should I hold or sell Dyne Therapeutics Inc. stock in 2025Build wealth steadily with proven investment techniques - Jammu Links News
What is the risk reward ratio of investing in Dyne Therapeutics Inc. stockAchieve breakthrough investment performance - Jammu Links News
How many analysts rate Dyne Therapeutics Inc. as a “Buy”Unlock powerful market insights for success - jammulinksnews.com
Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? - MSN
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - ADVFN Brasil
Pomerantz Investigates Dyne Therapeutics for Securities Fraud. - AInvest
Stifel Downgrades Dyne Therapeutics to Buy, Lowers PT to $36. - AInvest
Stifel lowers Dyne Therapeutics stock price target to $36 on endpoint changes - Investing.com Canada
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank - The Globe and Mail
Dyne Therapeutics (DYN) Keeps 'Outperform' Rating Amid RBC Capital Price Target Cut to $23.00 - AInvest
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.56%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):